Burkitt's lymphoma diagnostic study of choice: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 5: Line 5:


== Diagnostic Study of Choice ==
== Diagnostic Study of Choice ==
 
Biopsy of the affected lymph nodes remains to be the diagnostic study of choice which confirms Burkitts lymphoma.
=== Study of choice ===
=== Study of choice ===
[Name of the investigation] is the gold standard test for the diagnosis of [disease name].
* Lymph node or extra nodal tissue biopsy is diagnostic of Burkitt's lymphoma.
 
* To view the characteristic findings of Burkitt's lymphoma biopsy please click [[Burkitt's lymphoma pathophysiology #Microscopic Pathology|'''here''']].
OR
 
The following result of [gold standard test] is confirmatory of [disease name]:
* [Result 1]
* [Result 2]
 
OR
 
[Name of the investigation] must be performed when:
* The patient presents with [symptom/sign 1], [symptom/sign 2], and [symptom/sign 3].
* A [name of test] is positive for [sign 1], [sign 2], and [sign 3] in the patient.
 
OR
 
[Name of the investigation] is the gold standard test for the diagnosis of [disease name].
 
OR
 
The diagnostic study of choice for [disease name] is [name of the investigation].
 
OR
 
There is no single diagnostic study of choice for the diagnosis of [disease name].
 
OR
 
There is no single diagnostic study of choice for the diagnosis of [disease name], but [disease name] can be diagnosed based on [name of the investigation 1] and [name of the investigation 2].
 
OR
 
[Disease name] is primarily diagnosed based on the clinical presentation.
 
OR
 
Investigations:
* Among the patients who present with clinical signs of [disease name], the [investigation name] is the most specific test for the diagnosis.
* Among the patients who present with clinical signs of [disease name], the [investigation name] is the most sensitive test for diagnosis.
* Among the patients who present with clinical signs of [disease name], the [investigation name] is the most efficient test for diagnosis.
 
==== The comparison of various diagnostic studies for [disease name] ====
==Staging==
==Staging==
According to the Murphy staging system, there are four stages of Burkitt's lymphoma based on the number of nodes involved and the extra nodal spread.
According to the Murphy staging system, there are four stages of Burkitt's lymphoma based on the number of nodes involved and the extra nodal spread.
Line 101: Line 61:


===== Sequence of Diagnostic Studies =====
===== Sequence of Diagnostic Studies =====
The [name of investigation] must be performed when:
* The patient presented with symptoms/signs 1, 2, and 3 as the first step of diagnosis.
* A positive [test] is detected in the patient, to confirm the diagnosis.
OR
The various investigations must be performed in the following order:
The various investigations must be performed in the following order:
* [Initial investigation]
* [Initial investigation]
* [2nd investigation]
* [2nd investigation]


=== Name of Diagnostic Criteria ===
'''It is recommended that you include the criteria in a table. Make sure you always cite the source of the content and whether the table has been adapted from another source.'''
[Disease name] is primarily diagnosed based on clinical presentation. There are no established criteria for the diagnosis of [disease name].
OR
There is no single diagnostic study of choice for [disease name], though [disease name] may be diagnosed based on [name of criteria] established by [...].
OR
The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
OR
The diagnosis of [disease name] is based on the [criteria name] criteria, which includes [criterion 1], [criterion 2], and [criterion 3].
OR
[Disease name] may be diagnosed at any time if one or more of the following criteria are met:
* Criteria 1
* Criteria 2
* Criteria 3
OR
'''IF there are clear, established diagnostic criteria'''
The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
OR
The diagnosis of [disease name] is based on the [criteria name] criteria, which include [criterion 1], [criterion 2], and [criterion 3].
OR
The diagnosis of [disease name] is based on the [definition name] definition, which includes [criterion 1], [criterion 2], and [criterion 3].
OR
'''IF there are no established diagnostic criteria'''
There are no established criteria for the diagnosis of [disease name].


==References==
==References==

Revision as of 22:34, 2 January 2019

Burkitt's lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Burkitt's lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study Of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray Findings

CT

MRI

Biopsy

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Burkitt's lymphoma diagnostic study of choice On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Burkitt's lymphoma diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Burkitt's lymphoma diagnostic study of choice

CDC on Burkitt's lymphoma diagnostic study of choice

Burkitt's lymphoma diagnostic study of choice in the news

Blogs on Burkitt's lymphoma diagnostic study of choice

Directions to Hospitals Treating Burkitt's lymphoma

Risk calculators and risk factors for Burkitt's lymphoma diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Diagnostic Study of Choice

Biopsy of the affected lymph nodes remains to be the diagnostic study of choice which confirms Burkitts lymphoma.

Study of choice

  • Lymph node or extra nodal tissue biopsy is diagnostic of Burkitt's lymphoma.
  • To view the characteristic findings of Burkitt's lymphoma biopsy please click here.

Staging

According to the Murphy staging system, there are four stages of Burkitt's lymphoma based on the number of nodes involved and the extra nodal spread.

Staging for Burkitt's lymphoma is provided in the following table:[1]

Murphy staging system
Stage Features
Stage I
  • Single nodal or extra nodal site involvement excluding mediastinum or abdomen[2]
Stage II
  • Single extra nodal tumor with regional nodal involvement
  • Two extra nodal tumors on one side of diaphragm[2]
  • Primary gastrointestinal tumor with or without associated mesenteric nodes
  • Two or more nodal areas on one side of diaphragm
Stage IIR
  • Completely resected intra-abdominal disease
Stage III
  • Two single extra nodal tumors on opposite sides of diaphragm [2]
  • All primary intra thoracic tumors
  • All paraspinal or epidural tumors
  • All extensive primary intra-abdominal disease
  • Two or more nodal areas on opposite sides of diaphragm
Stage IIIA
  • Localized, non-resectable abdominal disease
Stage IIIB
  • Widespread multi organ abdominal disease
Stage IV
  • Initial CNS or bone marrow involvement (< 25%)
Diagnostic results

The following finding(s) on performing [investigation name] is(are) confirmatory for [disease name]:

  • [Finding 1]
  • [Finding 2]
Sequence of Diagnostic Studies

The various investigations must be performed in the following order:

  • [Initial investigation]
  • [2nd investigation]


References

  1. Perkins AS, Friedberg JW (2008). "Burkitt lymphoma in adults". Hematology Am Soc Hematol Educ Program: 341–8. doi:10.1182/asheducation-2008.1.341. PMID 19074108.
  2. 2.0 2.1 2.2 Sandlund JT (2012). "Burkitt lymphoma: staging and response evaluation". Br J Haematol. 156 (6): 761–5. doi:10.1111/j.1365-2141.2012.09026.x. PMC 3292702. PMID 22296338.

Template:WH Template:WS